Moderna的“mRNA个性化疫苗”首度成功 花旗看好中国mRNA相关企业中的公司

格隆汇
Aug 21
花旗研究8月20日发布的报告,Moderna三期试验的成功证明mRNA疫苗能够在肿瘤学领域产生具有临床意义的结果,但在更广泛应用于癌症治疗之前,仍有多项挑战有待解决,包括黑色素瘤以外适应症的临床疗效验证、新抗原筛选、脂质纳米颗粒(LNP)递送以及个性化生产等。花旗表示,看好中国mRNA相关企业中具备成熟平台、生产基础设施,以及能够将疫苗与自有肿瘤免疫药物联合使用的公司。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10